Monitor topline data from the pilot study in H2 2026 as a key catalyst — positive results could support advancement to pivotal trials and re-rate the stock. Given the early stage and use of healthy volunteers, interpret results cautiously regarding clinical efficacy in patients.
Price Chart
Executive Summary
Eton Pharmaceuticals has dosed the first patient in a pilot clinical study evaluating ET-700, its extended-release zinc acetate formulation for Wilson disease. Topline results are expected in H2 2026, with a pivotal trial planned for early 2027 if data are positive. The company projects peak U.S. sales could exceed $100 million if approved.
Key Facts
- First patient dosed in a pilot clinical trial for ET-700, an extended-release zinc acetate for Wilson disease.
- Study is a double-blinded, placebo-controlled trial in 36 healthy volunteers across three arms, using 64Cu PET imaging to assess intestinal copper absorption.
- Topline results expected in second half of 2026; pivotal study could begin in early 2027 if results are positive.
- ET-700 is being tested as a twice-daily formulation versus standard-of-care Galzin (zinc acetate) three times daily.
- Company projects ET-700 could achieve over $100 million in peak annual U.S. sales if approved.
Financial Impact
Potential peak sales >$100M in the U.S. if ET-700 is approved; no near-term revenue impact expected.
Risk Factors
- Pilot study uses healthy volunteers, not Wilson disease patients, limiting direct clinical applicability.
- Failure to demonstrate reduced copper absorption or safety issues could halt development.
- Market opportunity depends on adoption over existing generics and adherence to dosing regimen.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281436 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $52.88 | awaiting T+60 | — | $51.16 (−3.25%) |
Oct 6, 2026 21d ago | 144 | $54.88 | awaiting T+60 | — | $51.16 (−6.78%) |
Sep 28, 2026 29d ago | 8-K | $59.18 | awaiting T+60 | — | $51.16 (−13.55%) |
Aug 31, 2026 8w ago | Insider Cluster | $60.43 | awaiting T+60 | — | $51.16 (−15.34%) |
Aug 28, 2026 8w ago | Insider Cluster | $60.44 | awaiting T+60 | — | $51.16 (−15.35%) |
Aug 24, 2026 9w ago | Insider Cluster | $63.05 | awaiting T+60 | — | $51.16 (+18.86%) |
Aug 19, 2026 9w ago | 144 | $61.48 | awaiting T+60 | — | $51.16 (+16.79%) |
Aug 5, 2026 11w ago | 8-K | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 5, 2026 11w ago | Press Release | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 4, 2026 12w ago | 8-K | $45.83 | awaiting T+60 | — | $51.16 (+11.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers